



(12) Translation of
European patent specification

(11) NO/EP 3309157 B1

NORWAY

(19) NO

(51) Int Cl.

C07D 409/14 (2006.01) *A61P 31/12 (2006.01)* *C07D 471/08 (2006.01)*
A61K 31/12 (2006.01) *C07D 207/16 (2006.01)* *C07D 471/10 (2006.01)*
A61K 31/4025 (2006.01) *C07D 401/14 (2006.01)* *C07D 487/04 (2006.01)*
A61K 31/4178 (2006.01) *C07D 405/14 (2006.01)* *C07D 491/113 (2006.01)*
A61K 31/4184 (2006.01) *C07D 413/14 (2006.01)* *C07D 495/04 (2006.01)*
A61K 31/427 (2006.01) *C07D 417/14 (2006.01)* *C07F 5/02 (2006.01)*
A61K 45/06 (2006.01) *C07D 471/04 (2006.01)*

Norwegian Industrial Property Office

- (21) Translation Published 2020.01.27
- (80) Date of The European
Patent Office Publication of
the Granted Patent 2019.09.04
- (86) European Application Nr. 17190692.8
- (86) European Filing Date 2010.05.12
- (87) The European Application's
Publication Date 2018.04.18
- (30) Priority 2009.05.13, US, 177972 P
2009.07.10, US, 224745 P
2009.09.01, US, 238760 P
- (84) Designated Contracting
States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ;
IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ;
SM ; TR
Designated Extension
States: BA ; ME ; RS
- (62) Divided application EP3002281, 2010.05.12
- (73) Proprietor Gilead Pharmasset LLC, 333 Lakeside Drive, Foster City, CA 94404, USA
- (72) Inventor GUO, Hongyan, 333 Lakeside Drive, Foster City, CA 94404, USA
KATO, Darryl, 333 Lakeside Drive, Foster City, CA 94404, USA
KIRSCHBERG, Thorstens A., 333 Lakeside Drive, Foster City, CA 94404, USA
LIU, Hongtae, 333 Lakeside Drive, Foster City, CA 94404, USA
LINK, John O., 333 Lakeside Drive, Foster City, CA 94404, USA
MITCHELL, Michael L., 333 Lakeside Drive, Foster City, CA 94404, USA
PARRISH, Jay P., 333 Lakeside Drive, Foster City, CA 94404, USA
SQUIRES, Neil, 333 Lakeside Drive, Foster City, CA 94404, USA
SUN, Jianyu, 333 Lakeside Drive, Foster City, CA 94404, USA
TAYLOR, James, 333 Lakeside Drive, Foster City, CA 94404, USA
BACON, Elizabeth M., 333 Lakeside Drive, Foster City, CA 94404, USA
CANALES, Eda, 333 Lakeside Drive, Foster City, CA 94404, USA
CHO, Aesop, 333 Lakeside Drive, Foster City, CA 94404, USA
COTTPELL, Jeromy J., 333 Lakeside Drive, Foster City, CA 94404, USA
DESAI, Manoj C., 333 Lakeside Drive, Foster City, CA 94404, USA

HALCOMB, Randall L., 333 Lakeside Drive, Foster City, CA 94404, USA
 KRYGOWSKI, Evan S., 333 Lakeside Drive, Foster City, CA 94404, USA
 LAZERWITH, Scott E., 333 Lakeside Drive, Foster City, CA 94404, USA
 LIU, Qi, 333 Lakeside Drive, Foster City, CA 94404, USA
 MACKMAN, Richard, 333 Lakeside Drive, Foster City, CA 94404, USA
 PYUN, Hyung-Jung, 333 Lakeside Drive, Foster City, CA 94404, USA
 SAUGIER, Joseph H., 333 Lakeside Drive, Foster City, CA 94404, USA
 TRENKLE, James D., 333 Lakeside Drive, Foster City, CA 94404, USA
 TSE, Winston C., 333 Lakeside Drive, Foster City, CA 94404, USA
 VIVIAN, Randall W., 333 Lakeside Drive, Foster City, CA 94404, USA
 SCHROEDER, Scott D., 333 Lakeside Drive, Foster City, CA 94404, USA
 WATKINS, William J., 333 Lakeside Drive, Foster City, CA 94404, USA
 XU, Lianhong, 333 Lakeside Drive, Foster City, CA 94404, USA
 YANG, Zheng-Yu, 333 Lakeside Drive, Foster City, CA 94404, USA
 KELLAR, Terry, 333 Lakeside Drive, Foster City, CA 94404, USA
 SHENG, Xiaoning, 333 Lakeside Drive, Foster City, CA 94404, USA
 CLARKE, Michael O'Neil Hanrahan, 333 Lakeside Drive, Foster City, CA 94404, USA
 CHOU, Chien-hung, 333 Lakeside Drive, Foster City, CA 94404, USA
 GRAUPE, Michael, 333 Lakeside Drive, Foster City, CA 94404, USA
 JIN, Haolun, 333 Lakeside Drive, Foster City, CA 94404, USA
 MCFADDEN, Ryan, 333 Lakeside Drive, Foster City, CA 94404, USA
 MISH, Michael R., 333 Lakeside Drive, Foster City, CA 94404, USA
 METOBO, Samuel E., 333 Lakeside Drive, Foster City, CA 94404, USA
 PHILLIPS, Barton W., 333 Lakeside Drive, Foster City, CA 94404, USA
 VENKATARAMANI, Chandrasekar, 333 Lakeside Drive, Foster City, CA 94404, USA
 KIM, Chuong U., 333 Lakeside Drive, Foster City, CA 94404, USA

(74) Agent or Attorney OSLO PATENTKONTOR AS, Hoffsvveien 1A, 0275 OSLO, Norge

(54) Title **ANTIVIRAL COMPOUNDS**


(56) References

Cited: WO-A1-2009/020828
 WO-A1-2010/017401
 WO-A2-2008/021927
 WO-A1-2008/144380
 WO-A1-2009/102568
 WO-A2-2008/021928

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>


Patentkrav

1. Forbindelse med formel



eller et farmasøytisk akseptabelt salt deriv.

- 5 2. Forbindelse ifølge krav 1 med formel:



3. Farmasøytisk sammensetning omfattende forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt deriv; og minst en farmasøytisk akseptabel bærer.
- 10 4. Farmasøytisk sammensetning ifølge krav 3, videre omfattende minst et ytterligere terapeutisk middel.
5. Farmasøytisk sammensetning ifølge krav 4, hvor nevnte ytterligere terapeutiske middel er valgt fra gruppen bestående av ribavirinalogeter, NS3-
15 proteaseinhibitorer, NS5b-polymeraseinhibitorer, alfa-glukosidase-1-inhibitorer, hepato-beskyttende midler, ikke-nukleosidinhibitorer av HCV og andre medisiner for behandling av HCV.
6. Farmasøytisk sammensetning ifølge krav 3, videre omfattende en
20 nukleosidanalog.
7. Farmasøytisk sammensetning ifølge krav 6, hvor nevnte nukleosidanalog er valgt fra ribavirin, viraamidin, levovirin, et L-nukleosid og isatoribin.

8. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav for anvendelse i profylaktisk eller terapeutisk behandling av hepatitt C eller en hepatitt C-assosiert lidelse.
- 5 9. Forbindelse for anvendelse ifølge krav 8, videre omfattende administrasjon av minst ett ytterligere terapeutisk middel.
- 10 10. Forbindelse for anvendelse ifølge krav 9, hvor nevnte ytterligere terapeutiske middel er valgt fra gruppen bestående av ribavirinanaloger, NS3-proteaseinhibitorer, NS5b-polymeraseinhibitorer, alfa-glukosidase-1-inhibitorer, hepato-beskyttende midler, ikke-nukleosidinhibitorer av HCV og andre medisiner for behandling av HCV.
- 15 11. Forbindelse for anvendelse ifølge krav 10, hvor NS5b-polymeraseinhibitoren er en nukleotidinhibitor av HCV NS5b-polymerase.
12. Forbindelse for anvendelse ifølge krav 9, hvor nevnte ytterligere terapeutiske middel er en nukleosidanalogue.
- 20 13. Forbindelse for anvendelse ifølge krav 12, hvor nevnte nukleosidanalogue er valgt fra ribavirin, viraamidin, levovirin, et L-nukleosid og isatoribin.